natgillin/translations-raw huggingface dataset:
An increased frequency was noted when given as add-on to metformin and a sulfonylurea (empagliflozin 10 mg: 16.1%, empagliflozin 25 mg: 11.5%, placebo: 8.4%), and as add-on to insulin with or without metformin and with or without a sulphonylurea (empagliflozin 10 mg: 19.5%, empagliflozin 25 mg: 27.1%, placebo: 20.6% during initial 18 weeks treatment when insulin could not be adjusted; empagliflozin 10 mg: 36.1%, empagliflozin 25 mg: 34.8%, placebo 35.3% over the 78-week trial).
Večjo pogostnost so opazili pri uporabi kot dodatno zdravljenje z metforminom in sulfonilsečnino (empagliflozin 10 mg: 16,1 %, empagliflozin 25 mg: 11,5 %, placebo: 8,4 %) in kot dodatno zdravljenje z insulinom z metforminom ali brez njega ali s sulfonilsečnino ali brez nje (empagliflozin 10 mg: 19,5 %, empagliflozin 25 mg: 27,1 %, placebo: 20,6 % v prvih 18 tednih zdravljenja, ko insulina ni bilo mogoče prilagoditi; empagliflozin 10 mg: 36,1 %, empagliflozin 25 mg: 34,8 %, placebo 35,3 % v 78-tedenskem preskušanju).
An increased incidence and severity of renal tubular basophilia/hyalinisation, dilation and casts, as well as interstitial lymphocyte inflammation and arteriolar medial hypertrophy were found at an exposure of 8–13 (valsartan) and 7–8 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.
Pri izpostavljenosti, ki je bila za valsartan od 8- do 13-krat večja in za amlodipin od 7- do 8-krat večja kot ob kliničnih odmerkih 160 mg valsartana in 10 mg amlodipina, so ugotovili večjo pojavnostjo in izrazitost bazofilije/hialinizacije, dilatacije in cilindrov ledvičnih tubulov ter intersticijskega limfocitnega vnetja in hipertrofije arteriolarne medije.
An increased incidence and severity of renal tubular basophilia/hyalinisation, dilation and casts, as well as interstitial lymphocyte inflammation and arteriolar medial hypertrophy were found at an exposure of 8–13 (valsartan) and 7–8 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.
Pri izpostavljenosti, ki je bila za valsartan od 8- do 13krat večja in za amlodipin od 7- do 8-krat večja kot ob kliničnih odmerkih 160 mg valsartana in 10 mg amlodipina, so ugotovili večjo pojavnostjo in izrazitost bazofilije/hialinizacije, dilatacije in cilindrov ledvičnih tubulov ter intersticijskega limfocitnega vnetja in hipertrofije arteriolarne medije.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.
V skupni analizi neželenih učinkov zlomov kosti iz randomiziranih, kontrolniranih, dvojno slepih kliničnih preskušanj pri več kot 8100 s pioglitazonom in 7400 s primerjalnim zdravilom zdravljenimi bolniki, ki so se zdravili do 3,5 let, so opazili povečano incidenco zlomov kosti pri ženskah.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double-blind clinical trials in over 8,100 pioglitazone- and 7,400 comparator-treated patients, on treatment for up to 3.5 years.
V kumulativni analizi neželenih učinkov zlomov kosti iz randomiziranih, nadzorovanih, dvojno slepih kliničnih preskušanj, ki so zajela več kot 8.100 bolnikov, ki so se do 3,5 let zdravili s pioglitazonom, in 7.400 bolnikov, ki so se do 3,5 let zdravili s primerjalnim zdravilom, so opazili večjo pojavnost zlomov kosti pri ženskah.
An increased incidence of cardiac failure has been observed in clinical trials when rosiglitazone is used in combination with insulin.
V kliničnih preskušanjih so pri sočasni uporabi rosiglitazona in insulina poročali o večji pojavnosti srčnega popuščanja.
An increased incidence of congestive heart failure is associated with doxorubicin therapy at cumulative lifetime doses > 450 mg/m2 or at lower doses for patients with cardiac risk factors.
Zdravljenje z doksorubicinom v kumulativnem življenjskem odmerku > 450 mg/m2 ali v manjšem odmerku pri bolnikih s kardialnimi dejavniki tveganja je povezano s povečano incidenco kongestivnega srčnega popuščanja.
An increased incidence of embryo-loss has been observed in rabbits at high multiples of the clinical exposure and in the presence of maternal toxicity (see section 5.3)..
Pri kuncih so opazili večjo pogostnost izgube zarodkov pri visokih večkratnikih klinične izpostavljenosti in ob prisotnosti toksičnosti za samice (glejte poglavje 5.3).
An increased incidence of graft thrombosis was observed in the post-transplant period in recipients of extended criteria donor allografts (see section 4.8).
Pri prejemnikih ledvice po razširjenih kriterijih za darovani organ so po presaditvi poročali o večji pojavnosti tromboze presadka (glejte poglavje 4.8).
An increased incidence of haematological adverse reactions such as neutropenia and thrombocytopenia was observed in these patients during the phase III study (see section 4.8).
V klinični študiji III. faze so pri teh bolnikih opazili povečano incidenco hematoloških neželenih učinkov, kot sta nevtropenija in trombocitopenija.
An increased incidence of infections and serious infections was not observed in patients with lymphocyte counts <0.8x109/l or
Pri bolnikih s številom limfocitov < 0,8 x 109/l ali < 0,5 x 109/l niso opazili večje incidence okužb in resnih okužb.
An increased incidence of LVEF declines was also observed in patients treated with Perjeta in combination with trastuzumab and docetaxel; LVEF recovered to ≥50% in all patients.
Večja incidenca znižanj LVEF je bila opažena pri bolnikih, zdravljenih z zdravilom Perjeta v kombinaciji s trastuzumabom in docetakselom; LVEF se je vrnila na ≥ 50 % pri vseh bolnikih.
An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long- term exposure to pregabalin at exposures ≥ 5 times the mean human exposure at the maximum recommended clinical dose.
Opazili so povečano pojavnost atrofije retine pri starejših albino podganah, pri dolgotrajnih izpostavljenostih pregabalinu, ki so bile ≥ 5-krat večje od največje priporočene izpostavljenosti pri človeku.
An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long-term exposure to pregabalin at exposures≥ 5 times the mean human exposure at the maximum recommended clinical dose.
Opazili so povečano pojavnost atrofije retine pri starejših albino podganah, pri dolgotrajnih izpostavljenostih pregabalinu, ki so bile ≥ 5-krat večje od največje priporočene izpostavljenosti pri človeku.
An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.
Pri bolnikih, ki so prejemali zdravila z eritropoetinom, so opazili zvečano incidenco trombotičnih vaskularnih dogodkov (glejte poglavji 4.4 in 4.8 – Splošni).
An increased incidence of thrombotic vascular events (TVEs) has been observed in patients receiving ESAs (see section 4.4).
Pri bolnikih, ki so prejemali ESA, so opazili povečano incidenco trombotičnih žilnih dogodkov (TVE) (glejte poglavje 4.4).
An increased infection rate and impairment of the immune response cannot be excluded.
Večje stopnje okužb in okvare imunskega odziva ni mogoče izključiti.
an increased level of sugar in the blood
zvišan nivo sladkorja v krvi
An increased level of the enzyme that breaks down fats and of the enzyme that breaks down starch.
zvišanje vrednosti encima, ki razgrajuje maščobe, in zvišanje vrednosti encima, ki razgrajuje škrob
An increased level of the enzyme that breaks down lipids and of the enzyme that breaks down starch.
zvišanje vrednosti encima, ki razgrajuje maščobe, in zvišanje vrednosti encima, ki razgrajuje škrob
An increased relative risk for thromboembolic events was observed in the overall population (RR 1.62, 95% CI: 1.13, 2.31).
V celotni populaciji so opazili povečano relativno tveganje za trombembolične dogodke (relativno tveganje 1,62; 95-% interval zaupanja: 1,13; 2,31).
An increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischaemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4.
Pri uporabnicah CHC so opazili povečano tveganje za arterijske in venske trombotične in trombembolične dogodke, vključno z miokardnim infarktom, možgansko kapjo, tranzitornimi ishemičnimi atakami, vensko trombozo in pljučno embolijo, ki so podrobneje obravnavani v poglavju 4.4.
An increased risk of bleeding cannot be excluded in patients: with hereditary vitamin K dependent clotting factor deficiencies;
Povečanega tveganja za krvavitve ni mogoče izključiti pri bolnikih: ki imajo dedno pomanjkanje od vitamina K odvisnih faktorjev strjevanja krvi;
An increased risk of bleeding is possible when Efient is co- administered with heparin.
Povečano tveganje za krvavitev je možno, kadar sočasno dajemo zdravilo Efient s heparinom.
An increased risk of bleeding may also be observed in patients who receive early administration of INTEGRILIN (e.g. upon diagnosis) compared to receiving it immediately prior to PCI, as seen in the Early ACS trial.
Večje tveganje krvavitev se lahko pojavi tudi pri bolnikih, ki prejmejo zdravilo INTEGRILIN zgodaj (npr. ob postavitvi diagnoze), v primerjavi s tistimi, ki ga prejmejo tik pred perkutanim koronarnim posegom, kot je pokazala študija Early ACS.
an increased risk of bleeding, such as:
če imate povečano tveganje za krvavitve, na primer:
An increased risk of bone fracture has been observed in patients taking this type of medicines.
Pri bolnikih, ki jemljejo tovrstna zdravila, je bilo opaženo povečano tveganje za zlome kosti.
An increased risk of bone fracture has beenobserved in patients taking this type of medicines.
Pri bolnikih, ki jemljejo tovrstna zdravila, je bilo opaženo povečano tveganje za zlome kosti.
An increased risk of bone freactures has been observed in patients taking this type of medicines.
Pri bolnikih, ki jemljejo tovrstna zdravila, je bilo opaženo povečano tveganje za zlome kosti.
An increased risk of cervical cancer in long-term users of COCs (> 5 years) has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).
V nekaterih epidemioloških študijah so pri ženskah, ki so dalj časa (> 5 let) uporabljale COC, poročali o povečanem tveganju za nastanek raka materničnega vratu, vendar pa še teče polemika o tem, v kolikšni meri je to odkritje pripisati sočasnim dejavnikom spolnega obnašanja in drugim dejavnikom, kot je na primer humani papiloma virus (HPV).
An increased risk of cervical cancer in long-term users of COCs (> 5 years) has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).
V nekaterih epidemioloških študijah so pri ženskah, ki so dalj časa (> 5 let) uporabljale KPK, poročali o povečanem tveganju za nastanek raka materničnega vratu, vendar pa še teče polemika o tem, v kolikšni meri je to odkritje pripisati sočasnim dejavnikom spolnega obnašanja in drugim dejavnikom, kot je na primer humani papiloma virus (HPV).
An increased risk of DVT and PE is associated with the use of lenalidomide with dexamethasone in patients with multiple myeloma, and to a lesser extent in patients treated with melphalan and prednisone or as monotherapy in patients with myelodysplastic syndromes and mantle cell lymphoma treated with lenalidomide monotherapy (see section 4.5).
Zvečano tveganje globoke venske tromboze (GVT) in pljučne embolije (PE) je povezano z uporabo lenalidomida z deksametazonom pri bolnikih z diseminiranim plazmocitomom in v manjšem obsegu pri bolnikih, zdravljenih z melfalanom in prednizonom ali z monoterapijo pri bolnikih z mielodisplastičnimi sindromi in limfomom plaščnih celic, zdravljenimi z monoterapijo z lenalidomidom (glejte poglavje 4.5).
An increased risk of ICH has previously been observed in patients with advanced HIV disease/AIDS such as those treated in the Aptivus clinical trials.
Povečano tveganje možganskih krvavitev so že prej zasledili pri bolnikih z napredovalo boleznijo zaradi okužbe s HIV oziroma aidsom, na primer pri tistih, ki so se zdravili v sklopu kliničnih preskušanj zdravila Aptivus.
An increased risk of ILD on gefitinib relative to chemotherapy was seen predominantly during the first 4 weeks of treatment (adjusted OR 3.8; 95% CI 1.9 to 7.7); thereafter the relative risk was lower (adjusted OR 2.5; 95% CI 1.1 to 5.8).
Večje tveganje za IBP so med uporabo gefitiniba v primerjavi s kemoterapijo ugotovili predvsem v prvih 4 tednih zdravljenja (korigirano razmerje obetov 3,8; 95 % IZ od 1,9 do 7,7); pozneje se je relativno tveganje zmanjšalo (korigirano razmerje obetov 2,5; 95 % IZ od 1,1 do
An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm3 (6.3 % versus 1.2 % for men with CD4 counts <400 cells/mm3).
Povečano tveganje so zasledili tudi pri moških z izmerljivo ravnijo HIV-1 RNA v plazmi in s številom celic CD4 > 400 celic/mm3 (6,3 % proti 1,2 % pri moških s številom celic CD4 < 400 celic/mm3).
An individual patient data based meta-analysis, which included data from all 12 controlled clinical studies in anaemic cancer patients conducted with NeoRecormon (n=2301), showed an overall hazard ratio point estimate for survival of 1.13 in favour of controls (95 % CI 0.87, 1.46).
Meta analiza podatkov posameznih bolnikov, v katero so bili vključeni podatki iz 12 vseh kontroliranih kliničnih študij, izvedenih z zdravilom NeoRecormon pri bolnikih z rakom, ki so imeli anemijo (n = 2301), je pokazala, da je ocena celokupnega razmerja ogroženosti za preživetje 1,13 v prid kontrolni skupini (95-% interval zaupanja 0,87; 1,46).
An individual patient data based meta-analysis, which included data from all 12 controlled clinical studies in anaemic cancer patients conducted with NeoRecormon (n=2301), showed an overall hazard ratio point estimate for survival of 1.13 in favour of controls (95 % CI 0.87, 1.46).
Meta analiza podatkov posameznih bolnikov, v katero so bili vključeni podatki iz vseh 12 kontroliranih kliničnih študij, izvedenih z zdravilom NeoRecormon, pri bolnikih z rakom, ki so imeli anemijo (n = 2301), je pokazala, da je ocena celokupnega razmerja ogroženosti za preživetje 1,13 v prid kontrolni skupini (95-% interval zaupanja 0,87; 1,46).
An infection called “thrush” which can affect the gut and is caused by a fungus.
okužba, ki jo imenujemo "gobice" in lahko prizadene črevo; povzročajo jo glivice
An infection characterised by high fever, sore throat, skin lesions and an extreme reduction of white blood cells (agranulocytosis).
infekcija, za katero je značilna visoka vročina, boleče grlo, rane na koži in izrazito zmanjšanje belih krvnih celic (agranulocitoza),
An infection could also give you a raised temperature (fever).
Okužba je lahko tudi vzrok zvišane telesne temperature (vročine).
An infection in your urine.
okužba sečil
an infection of the blood caused by bacteria - this may be a sign of a low level of white blood cells
bakterijska okužba krvi - je lahko znak znižanega števila belih krvnih celic
An infection of the blood caused by bacteria.
bakterijska okužba krvi,
An infection of the genitals caused by a fungus (thrush)
glivična okužba spolovil (gobice)
an infection of the lungs called “pneumonia” infections caused by bacteria that other antibiotics may not be able to kill
okužbe pljuč, ki jo imenujemo "pljučnica", okužb z bakterijami, ki jih drugi antibiotiki morda ne morejo uničiti.
An infection of the nose and throat, or sore throat.
okužba nosu in žrela ali vneto žrelo
An infection or a fever
Imate okužbo ali zvišano telesno temperaturo.
An infection which affects your whole body (e.g., sepsis, seen as high temperature, increased heart rate or breathing)
okužba, ki je prizadela celo telo (npr. sepsa, ki se kaže kot zvišana telesna temperatura, hitrejši srčni utrip ali hitrejše dihanje)
An infection with Human Immunodeficiency Virus (HIV) without showing symptoms of HIV disease.
Okužba s človeškim virusom imunske pomanjkljivosti (HIV) brez znakov bolezni HIV.
an infection,
okužbo,
an infection;
okužbo;
An inflammatory condition of the skin characterised by redness, itching, and oozing liquid- filled cysts which become scaly, crusted, or hardened (dermatitis acneiform)
vnetna bolezen kože, pri kateri pride do rdečine, srbenja in nastajanja mehurčkov, napolnjenih s tekočino, ki se kasneje luščijo, razvijejo v kraste ali se posušijo (akneiformni dermatitis)
An infusion bag may contain any of the following: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, sodium chloride 4.5 mg/mL and dextrose 25 mg/mL solution for injection (0.45% sodium chloride and 2.5% dextrose) or Lactated Ringer’s solution.
Infuzijska vrečka lahko vsebuje kar koli od naslednjega: 0,9 % (9 mg/ml) raztopino natrijevega klorida za injiciranje, 5 % (50 mg/ml) raztopino glukoze za injiciranje, raztopino 4,5 mg/ml natrijevega klorida in 25 mg/ml glukoze za injiciranje (0,45 % natrijevega klorida in 2,5 % glukoze) ali raztopino Ringerjevega laktata.
An infusion pump is the preferred delivery device.
Zdravilo je treba po možnosti dati z infuzijsko črpalko.
An infusion reaction is any side effect, including an allergic reaction, occurring during the infusion or within a day following infusion (see section 4 “Possible side effects”).
Z infuzijo povezana reakcija je vsak neželeni učinek, vključno z alergijsko reakcijo, ki se pojavi med infundiranjem ali v enem dnevu po prejemu infuzije (glejte poglavje 4 »Možni neželeni učinki«).
An infusion reaction was defined in the pivotal trial CLEOPATRA in metastatic breast cancer as any event reported as hypersensitivity, anaphylactic reaction, acute infusion reaction or cytokine release syndrome occurring during an infusion or on the same day as the infusion.
Infuzijska reakcija je bila v ključnem preskušanju CLEOPATRA pri metastatskem raku dojk opredeljena kot vsak dogodek, poročan kot preobčutljivost, anafilaktična reakcija, akutna infuzijska reakcija ali sindrom sproščanja citokinov, ki se je pojavil med infuzijo ali na dan infuzije.
An infusion set equipped with an in-line 0.2 µm filter can be used.
Uporabite lahko infuzijski komplet, opremljen z 0,2-µm linijskim filtrom.
An infusion set equipped with an in-line 0.2µm filter can be used.
Uporabite lahko infuzijski komplet, opremljen z 0,2-µm linijskim filtrom.
An infusion- associated reaction can sometimes be very severe.
Infuzijske reakcije so lahko včasih zelo hude.
An infusion- associated reaction is any side effect occurring during the infusion or until the end of the infusion day (see section 4).
Reakcija, povezana z infuzijo, je vsak neželeni učinek, do katerega pride med infundiranjem ali do konca dneva, na katerega ste prejeli infuzijo (glejte poglavje 4).
An initial
Razmisliti je
An initial dose of 6 mg contains up to 150 mg of alcohol which isequivalent to 3 mL beer or 1.25 mL wine.
Šestmiligramski začetni odmerek vsebuje do 150 mg alkohola, kar ustreza 3 ml piva ali 1,25 ml vina.
An initial dose of 90 µg per kg body weight is recommended and could be administered on the way to the hospital where the patient is usually treated.
Priporočen je začetni odmerek 90 µg na kg telesne mase; aplicirati ga je mogoče na poti v bolnišnico, kjer ponavadi poteka zdravljenje.
An instruction how to take Pradaxa
Navodila za jemanje zdravila Pradaxa
An interaction is possible.
(sakvinavir/ritonavir
An interaction study between bosentan and lopinavir+ritonavir in healthy subjects showed increased plasma concentrations of bosentan, with the maximum level during the first 4 days of treatment (see section 4.5).
Študija medsebojnega delovanja med bosentanom in lopinavirjem in ritonavirjem pri zdravih prostovoljcih je pokazala zvišane koncentracije bosentana v plazmi z največjo ravnijo v prvih 4 dneh zdravljenja (glejte poglavje 4.5).
An interaction study with gemfibrozil, an in vitro inhibitor of OAT3 and OATP1B1/1B3 transporters, showed that empagliflozin Cmax increased by 15% and AUC increased by 59% following co- administration.
Študija medsebojnega delovanja z gemfibrozilom, ki je in vitro zaviralec OAT3 in prenašalcev OATP1B1/1B3, je pokazala, da se je po sočasni uporabi Cmax empagliflozina povečal za 15 %, AUC pa za 59 %.
An interaction study with protein-conjugated vaccine against Neisseria menigitidis serogroup C has been investigated in children aged 2-11 years.
Beljakovinsko konjugirano cepivo proti bakteriji Neisseria meningitidis seroskupine C so preučevali v študiji medsebojnega delovanja pri otrocih starih od 2 do 11 let.
An interaction with trimethoprim, a constituent of co-trimoxazole, causes a 40% increase in lamivudine exposure at therapeutic doses.
Interakcija s trimetoprimom, ki je sestavina kotrimoksazola, pri terapevtskih odmerkih izpostavljenost lamivudinu poveča za 40%.
An interim analysis of RE-VERSE AD included data for 123 patients: 66 patients with serious bleeding (Group A) and 57 requiring an urgent procedure (Group B).
Vmesna analiza RE-VERSE AD je vključevala podatke 123 bolnikov: 66 bolnikov z resnimi krvavitvami (skupina A) in 57 bolnikov, ki so potrebovali nujne posege (skupina B).
An interim analysis was performed when all subjects had completed the month 48 study visit.
Vmesna analiza je bila narejena, ko so vse preiskovanke opravile obisk ob 48. mesecu študije.
An international, multicenter, randomized, open-label, comparative Phase 3 efficacy and safety study was conducted in newly diagnosed Ph+ CP CML patients.
Izvedli so mednarodno, multicentrično, randomizirano, odprto, primerjalno študijo 3. faze pri bolnikih z novo odkrito Ph+ KML v kronični fazi, v kateri so ocenjevali učinkovitost in varnost.
An interruption of dosing should be considered if intense local inflammatory reactions occur (see section 4.4) or if infection is observed at the treatment site.
Zdravljenje je potrebno za nekaj dni prekiniti (glejte poglavje 4.4), če lokalna kožna reakcija na imikvimod kremo povzroči prekomerno nelagodje bolnika ali če se na področju zdravljenja razvije okužba.
An intravenous microdrip chamber can provide a convenient range of infusion rates within the recommended dose levels for atosiban.
Intravenska mikrokapalna komora lahko zagotavlja ustrezen razpon hitrosti infundiranja v priporočenih odmernih mejah za infundiranje atosibana.
An introduction in each guide will inform the reader that the purpose of the guide is to tell them that a foetal exposure must be avoided and how to minimize the risk of birth defects and miscarriage associated with mycophenolate mofetil.
uvod v obeh vodnikih bo informiral bralca, da je namen vodnika pojasniti, da se je treba izogibati izpostavljenosti ploda in kako kar najbolj zmanjšati tveganje za prirojene okvare in spontani splav, povezane z uporabo mofetilmikofenolata.
An irritation of the eyes (conjunctivitis).
draženje oči (konjunktivitis)
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces.
N-desmetilni presnovek, za katerega je celični test dokazal, da ima podobno ali manjšo aktivnost od matične spojine, so odkrili v seču, plazmi in blatu.
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma, and faeces.
Presnovek N-desmetil, za katerega so v celičnem testu dokazali, da ima podobno ali manjšo aktivnost kot izvorna učinkovina, so odkrili v urinu, plazmi in blatu.
An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine.
V seču so odkrili O- glukuronidacijski presnovek topotekana in N-desmetil topotekan.
An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine.
V urinu so odkrili O- glukuronidacijski presnovek topotekana in N-desmetil topotekan.